[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:systemic-scleroderma:anti-ds-dna-antibody":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Systemic Scleroderma","Anti-ds DNA Antibody",3,[8,16,24],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06434363","Phase I\u002FII Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:52.966503Z","2026-05-05T02:43:26.675534Z",{"nct_id":17,"title":18,"phases":19,"status":21,"updated_at":22,"content_modified":23},"NCT07729995","BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease",[20],"Phase 1","NOT_YET_RECRUITING","2026-08-26T02:15:03.757872Z","2026-07-30T01:46:14.459181Z",{"nct_id":25,"title":26,"phases":27,"status":28,"updated_at":29,"content_modified":30},"NCT07038447","A Study of KITE-363 in Participants With Refractory Autoimmune Diseases",[20],"ENROLLING_BY_INVITATION","2026-08-26T02:15:11.740957Z","2026-06-16T05:54:07.853790Z"]